Phase I/II and Phase II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Chemotherapy-resistant Sarcoma and Osteosarcoma

Rexin-G, a pathotropic nanoparticle bearing a cytocidal cyclin G1 construct was tested in a phase I/II study for chemotherapy-resistant sarcomas and a phase II study for chemotherapy-resistant osteosarcoma. Twenty sarcoma patients and 22 osteosarcoma patients received escalating doses of Rexin-G int...

Descripción completa

Detalles Bibliográficos
Autores principales: Chawla, Sant P, Chua, Victoria S, Fernandez, Lita, Quon, Doris, Saralou, Andreh, Blackwelder, William C, Hall, Frederick L, Gordon, Erlinda M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835268/
https://www.ncbi.nlm.nih.gov/pubmed/19532136
http://dx.doi.org/10.1038/mt.2009.126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835268/
https://www.ncbi.nlm.nih.gov/pubmed/19532136
http://dx.doi.org/10.1038/mt.2009.126

Ejemplares similares